Bibliography
Found 39 results
Filters: Keyword is Antiretroviral Therapy, Highly Active [Clear All Filters]
White matter damage, neuroinflammation, and neuronal integrity in HAND. J Neurovirol. 2019 ;25(1):32-41.
Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS. 2009 ;23(17):2317-22.
. Better executive function is independently associated with full HIV suppression during combination therapy. AIDS. 2019 ;33(15):2309-2316.
. Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2015 ;69(1):29-35.
Brain morphometric correlates of metabolic variables in HIV: the CHARTER study. J Neurovirol. 2014 ;20(6):603-11.
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology. 2013 ;81(17):1492-9.
Exosome markers associated with immune activation and oxidative stress in HIV patients on antiretroviral therapy. Sci Rep. 2018 ;8(1):7227.
. Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother. 2012 ;56(4):1985-9.
Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol. 2008 ;64(5):566-72.
Factors related to HIV-associated neurocognitive impairment differ with age. J Neurovirol. 2015 ;21(1):56-65.
. When do models of NeuroAIDS faithfully imitate "the real thing"?. J Neurovirol. 2018 ;24(2):146-155.
. Older age and plasma viral load in HIV-1 infection. AIDS. 2004 ;18 Suppl 1:S87-98.
Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 ;82(23):2055-62.
. Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. J Neurovirol. 2016 ;22(4):479-87.
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010 ;75(23):2087-96.
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. J Infect Dis. 2016 ;213(7):1065-73.
Brain-specific HIV Nef identified in multiple patients with neurological disease. J Neurovirol. 2018 ;24(1):1-15.
. Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy. Clin Infect Dis. 2018 ;67(5):770-777.
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 ;65(1):65-70.
Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV. 2019 ;6(7):e456-e462.